LLS Forms Partnership With Forma

The Leukemia & Lymphoma (LLS) and Forma have signed a partnership to accelerate LLS’s pipeline of research projects entering late pre-clinical development.

Repotedly, the collaboration will begin with a selection of ten small molecule candidates (discovered by LLS grant-funded academic researchers) deemed to have the most promise of advancing into clinical trials in the shortest period of time.

Forma will use its proprietary Computational Solvent (CS) Mapping technology to aid in structure-based drug design with expert computer modeling, screening and medicinal chemistry competence, to optimize and prioritize molecules that LLS and its partners may take to the clinic.

The partnership between LLS and Forma is the latest in LLS’s Therapy Acceleration Program (TAP). Through TAP, LLS is taking a result-oriented approach, partnering directly with biotechnology companies to move promising therapies more quickly along the FDA drug approval critical path.

Steve Tregay, CEO of Forma, said: “LLS has assembled a promising portfolio of innovative programs to combat a wide range of hematological cancers. The team at Forma is excited to be working with LLS on this bold initiative by providing our unique suite of drug discovery technologies to quickly translate science from the laboratory to patients in clinical trials.”